Maximum haldol decanoate dose

The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.

If you have commercial or private health insurance and need help paying for ZYTIGA®, the Janssen CarePath Savings Program for ZYTIGA® may provide an instant savings for your out-of-pocket ZYTIGA® costs. If eligible, you will pay $10 per month for up to $12,000 maximum annual benefit. If you are using Medicare, Medicaid, or other federally funded programs to pay for ZYTIGA® medication, you are not eligible to participate in this program. To learn more about the program, including eligibility and restrictions, click here .

Given these considerations, antipsychotic drugs should be prescribed in a manner that is most likely to minimize the occurrence of tardive dyskinesia. Chronic antipsychotic treatment should generally be reserved for patients who suffer from a chronic illness that 1) is known to respond to antipsychotic drugs, and 2) for whom alternative, equally effective, but potentially less harmful treatments are not available or appropriate. In patients who do require chronic treatment, the smallest dose and the shortest duration of treatment producing a satisfactory clinical response should be sought. The need for continued treatment should be reassessed periodically.

Maximum haldol decanoate dose

maximum haldol decanoate dose


maximum haldol decanoate dosemaximum haldol decanoate dose